SLAMF6 receptor is a novel potential target for the modulation of T cell anti-tumor activity!
In the study now published by Emma Hajaj, MD. PhD. student from Prof. Michal Lotems’ lab, the SLAMF6 receptor deficiency is crucial for the success of adoptive T cell therapy in mice, supporting the notion that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8+ T cells to eradicate tumors.
Congratulations! Prof. Ofer Mandelboim for recieving the Rappaport Prize
The prize for an Established Researcher was given to Ofer for his many works on how Natural Killer cells recognize viruses.